You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
方盛製藥(603998.SH):綠合製藥已收到正申科技支付合計2780萬元轉讓款
格隆匯 08-01 16:54

格隆匯8月1日丨方盛製藥(603998.SH)公佈,公司於2024年2月27日與全資子公司綠合製藥、正申科技、新盤生物、自然人梁步閣先生共同簽署《股權轉讓協議》,將綠合製藥持有的新盤生物100%股權轉讓予正申科技,轉讓價格為5,200萬元人民幣(詳見公司2024-019號公吿)。截至本公吿披露日,綠合製藥已收到正申科技支付的第一期轉讓款700萬元及第二期轉讓款2,080萬元,合計2,780萬元。

根據《股權轉讓協議》約定,正申科技支付第二期股權轉讓款後,將以湖南新盤生物科技有限公司(以下簡稱“新盤生物”)的資產作為抵押向銀行申請貸款,獲取的貸款將用於支付至綠合製藥作為股權轉讓款;而正申科技以新盤生物的資產作為抵押向銀行申請貸款具有一定的不確定性,即綠合製藥將新盤生物100%股權轉讓至正申科技最終能否完成具有一定的不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account